Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Medtronic Enterra™ Therapy for Gastroparesis: Patient should always discuss the potential risks and benefits of the device with the physician.
The Enterra™ Therapy System for gastric electrical stimulation (GES) is indicated for use in the treatment of chronic, intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
The Enterra™ Therapy System is not intended for patients whom the physician determines are not candidates for surgical procedures and/or anaesthesia due to physical or mental health conditions. You cannot have diathermy (deep heat treatment from electromagnetic energy) if you have an Enterra™ device.
This system has not been evaluated for pregnant women, for use in patients under the age of 18, or patients over the age of 70. Strong sources of electromagnetic interference (EMI) can result in serious injury, system damage, or operational changes to the system. The system may be affected by or adversely affect cardiac devices, electrocautery, defibrillators, ultrasonic equipment, radiofrequency (RF)/microwave ablation, radiation therapy, MRI and theft detectors/screening devices. Patients on anticoagulation therapy may be at a greater risk for post-operative complications. The use of non-Medtronic components with this system may result in damage to Medtronic components, loss of therapy, or patient injury. There is the possibility of an allergic or immune system response to the implanted materials. When possible, a physician is to identify and treat any infections prior to surgery. Infections at the implant site almost always require the surgical removal of the implanted system. The lead can become entangled with the bowel and cause life-threatening blockage or infections that require immediate medical attention, and may require surgery.
Patients should avoid activities that may put undue stress on the implanted system components (activities that include sudden, excessive, or repetitive bending, twisting, bouncing, or stretching that can cause component fracture or dislodgment).
Adverse events related to the therapy, device, or procedure can include: infection, pain at the surgery site, device components may wear through the skin, bruising at the neurostimulator site, bleeding, loss of therapeutic effect, undesirable change in stimulation (described as a jolting, shocking or burning sensation), and gastrointestinal complications (in that the lead may perforate your stomach or device components may become entangled with or obstruct other internal organs, requiring surgery). The system could stop because of mechanical or electrical problems. Any of these situations may require additional surgery or cause your symptoms to return.
Authorised for use in the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
For further information, please consult Medtronic’s website at www.medtronic.com.